Abstract
Vascular malformation, a key clinical phenotype of Proteus syndrome, lacks effective models for pathophysiological study and drug development due to limited patient sample access. To bridge this gap, we built a human vascular organoid model replicating Proteus syndrome's vasculature. Using CRISPR/Cas9 genome editing and gene overexpression, we created induced pluripotent stem cells (iPSCs) embodying the Proteus syndrome-specific AKT<sup>E17K</sup> point mutation for organoid generation. Our findings revealed that AKT overactivation in these organoids resulted in smaller sizes yet increased vascular connectivity, although with less stable connections. This phenomenon likely stems from boosted vasculogenesis triggered by AKT overactivation, leading to increased vascular sprouting. Additionally, a notable increase in dysfunctional PDGFR$β$+ mural cells, impaired in matrix secretion, was observed in these AKT-overactivated organoids. The application of AKT inhibitors (ARQ092, AZD5363, or GDC0068) reversed the vascular malformations; the inhibitors' effectiveness was directly linked to reduced connectivity in the organoids. In summary, our study introduces an innovative in vitro model combining organoid technology and gene editing to explore vascular pathophysiology in Proteus syndrome.
Introduction
Proteus syndrome (PS) is an ultra-rare genetic disorder characterized by the overgrowth of bone, skin, and vasculature. The disease is caused by a mosaic point mutation ($E17K$) in the AKT1 gene, meaning the mutation is only present in a subset of the patient's cells. This mosaicism, combined with the scarcity of patient samples, makes PS exceptionally difficult to study using traditional methods. Animal models often fail to replicate human-specific responses, and 2D cultures cannot capture the complex 3D architecture of malformed vessels. This study aims to create a high-fidelity 3D human vascular organoid model to investigate PS pathophysiology and screen potential therapeutics.
Methods
The researchers developed a multi-step pipeline to model the disease in vitro. First, human induced pluripotent stem cells (iPSCs) were edited using CRISPR/Cas9 and homology-directed repair (HDR) to introduce the $AKT1^{E17K}$ mutation. The goal was to achieve a mosaic mutation rate (approximately 50%) to mirror clinical presentations. These edited iPSCs were then differentiated into 3D vascular organoids containing both endothelial cells and supporting mural cells.
To analyze the resulting vascular networks, the team utilized CLARITY-optimized light sheet microscopy for deep tissue imaging. Quantitative analysis was performed using the VesSAP (Vessel Segmentation and Analysis Pipeline) framework, which employs deep learning to segment vessels and analyze network topology, including connectivity and branching.
Results
Validation of Mosaicism and AKT Overactivation
The CRISPR/Cas9 approach successfully generated iPSC pools with mutation rates ranging from 28% to 50%. Validation through Sanger sequencing and Western blotting confirmed the presence of the $E17K$ mutation and a corresponding increase in AKT protein levels compared to wild-type controls.
Vascular Phenotype: "Smaller but Busier"
Organoids carrying the $AKT1$ mutation were smaller in overall size but exhibited significantly higher vascular connectivity and sprouting. This "smaller but busier" paradox suggests that AKT overactivation drives rapid but disorganized vasculogenesis. While these networks had higher bifurcation density, they were structurally unstable, characterized by a lower degree exponent in network analysis.
Mural Cell Dysfunction and Drug Rescue
A critical finding was the role of $PDGFRβ$+ mural cells. In mutant organoids, these cells showed impaired matrix secretion, leading to a lack of structural support for the vessels. This deficiency contributes to the leakiness and malformation observed in PS.
The model's utility for drug screening was demonstrated by testing AKT inhibitors. ARQ092 (Miransertib) was the most effective at reversing vascular overgrowth, correlating with its high potency against AKT1. Notably, CRISPR-edited lines provided more predictable drug responses than overexpression models, emphasizing the value of precise genomic editing.
Conclusion
This study presents the first human vascular organoid model of Proteus syndrome. By combining CRISPR/Cas9 editing with 3D organoid technology and AI-driven imaging analysis, the researchers successfully recapitulated the complex vascular malformations of the disease. While limited to vascular tissue, this model provides a powerful platform for studying rare mosaic disorders and accelerating drug development. Future work may involve multi-lineage organoids to study the systemic effects of the $AKT1$ mutation across different tissues.
Summary updated